The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD

Neurology

Volumn 62, Issue 2, 2004, Pages 330-332

  Schwid, S R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEP 1347; LEVODOPA; PLACEBO;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; MULTICENTER STUDY; NAUSEA; NERVE CELL NECROSIS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; VOMITING;

EID: 0842324952     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000103882.56507.20     Document Type: Article

References (8)

1. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997;12:25-31.
2. Hirsch EC, Hunot S, Faucheux B, et al. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord 1999;14:383-385.
3. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 2000;97:2875-2880.
4. Maroney AC, Finn JP, Bozyczko-Coyne D, et al. CEP1347 (KT 7515) and inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by 3 distinct insults. J Neurochem 1999;73:1901-1912.
5. Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 1999;288:421-427.
6. Saporito MS, Thomas BA, Scott RW. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 2000;75:1200-1208.
7. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CO, Calne DB, Goldstein M, eds. Recent development in Parkinson's disease, vol. 2. Florham Park: Macmillan Health Care Information, 1987:153-164.
8. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.